ERAS
Erasca, Inc.
Key Financials
Operating Income
$-140905000
↑ 21.5%
Net Income
$-124546000
↑ 23.0%
EPS (Diluted)
$-0.44
↑ 36.2%
Total Assets
$396.2M
↓ 21.2%
Cash & Equivalents
$73.8M
↑ 9.0%
Shareholders' Equity
$325.2M
↓ 23.2%
Total Liabilities
$71.0M
↓ 10.2%
Dividends/Share
$0.00
NaN%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 4 | 8/12/2026 | View on SEC |
| 3 | 8/12/2026 | View on SEC |
| S-8 | 8/11/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| 144 | 7/21/2026 | View on SEC |
| 8-K | 7/14/2026 | View on SEC |
| 424B5 | 7/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ERAS |
| Company Name | Erasca, Inc. |
| CIK | 1761918 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 465-6511 |